A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer
Manijeh Goldberg, Aaron Manzi, Amritpreet Birdi, Brandon Laporte, Peter Conway, Stefanie Cantin, Vasudha Mishra, Alka Singh, Alexander T Pearson, Eric R Goldberg, Sam Goldberger, Benjamin Flaum, Rifat Hasina, Nyall R London, Gary L Gallia, Chetan Bettegowda, Simon Young, Vlad Sandulache, James Melville, Jonathan Shum, Sonya E O'Neill, Erkin Aydin, Alex Zhavoronkov, Anxo Vidal, Atenea Soto, Maria Jose Alonso, Ari J Rosenberg, Mark W Lingen, Anil D'Cruz, Nishant Agrawal, Evgeny Izumchenko, Manijeh Goldberg, Aaron Manzi, Amritpreet Birdi, Brandon Laporte, Peter Conway, Stefanie Cantin, Vasudha Mishra, Alka Singh, Alexander T Pearson, Eric R Goldberg, Sam Goldberger, Benjamin Flaum, Rifat Hasina, Nyall R London, Gary L Gallia, Chetan Bettegowda, Simon Young, Vlad Sandulache, James Melville, Jonathan Shum, Sonya E O'Neill, Erkin Aydin, Alex Zhavoronkov, Anxo Vidal, Atenea Soto, Maria Jose Alonso, Ari J Rosenberg, Mark W Lingen, Anil D'Cruz, Nishant Agrawal, Evgeny Izumchenko
Abstract
Despite therapeutic advancements, oral cavity squamous cell carcinoma (OCSCC) remains a difficult disease to treat. Systemic platinum-based chemotherapy often leads to dose-limiting toxicity (DLT), affecting quality of life. PRV111 is a nanotechnology-based system for local delivery of cisplatin loaded chitosan particles, that penetrate tumor tissue and lymphatic channels while avoiding systemic circulation and toxicity. Here we evaluate PRV111 using animal models of oral cancer, followed by a clinical trial in patients with OCSCC. In vivo, PRV111 results in elevated cisplatin retention in tumors and negligible systemic levels, compared to the intravenous, intraperitoneal or intratumoral delivery. Furthermore, PRV111 produces robust anti-tumor responses in subcutaneous and orthotopic cancer models and results in complete regression of carcinogen-induced premalignant lesions. In a phase 1/2, open-label, single-arm trial (NCT03502148), primary endpoints of efficacy (≥30% tumor volume reduction) and safety (incidence of DLTs) of neoadjuvant PRV111 were reached, with 69% tumor reduction in ~7 days and over 87% response rate. Secondary endpoints (cisplatin biodistribution, loco-regional control, and technical success) were achieved. No DLTs or drug-related serious adverse events were reported. No locoregional recurrences were evident in 6 months. Integration of PRV111 with current standard of care may improve health outcomes and survival of patients with OCSCC.
Conflict of interest statement
M.G., A.M., A.B., B.L., P.C., S.C., B.F. and E.R.G. are affiliated with Privo Technologies. N.A. and S.G. serve as advisors for Privo Technologies. The remaining authors declare no competing interests.
© 2022. The Author(s).
Figures
References
- Howlader N, N. A. et al. (eds). SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, , based on November 2019 SEER data submission, posted to the SEER web site, April 2020. (2020).
- Kramer S, et al. Combined radiation-therapy and surgery in the management of advanced head and neck-cancer - final report of study 73-03 of the radiation-therapy-oncology-group. Head. Neck Surg. 1987;10:19–30. doi: 10.1002/hed.2890100105.
- Brizel DM, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 1998;338:1798–1804. doi: 10.1056/NEJM199806183382503.
- Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J. Clin. Oncol. 2004;22:1743–1752. doi: 10.1200/JCO.2004.06.147.
- Pignon JP, Bourhis J, Domenge C, Designe L, Grp MNC. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet. 2000;355:949–955. doi: 10.1016/S0140-6736(00)90011-4.
- Wang TJ, et al. Influences of facial disfigurement and social support for psychosocial adjustment among patients with oral cancer in Taiwan: a cross-sectional study. BMJ Open. 2018;8:e023670. doi: 10.1136/bmjopen-2018-023670.
- Kam D, et al. Incidence of suicide in patients with head and neck cancer. JAMA Otolaryngol. Head. Neck Surg. 2015;141:1075–1081. doi: 10.1001/jamaoto.2015.2480.
- Johnson DE, et al. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 2020;6:92. doi: 10.1038/s41572-020-00224-3.
- Machiels JP, et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up††These Guidelines were developed by the European Head and Neck Society (EHNS), the European Society for Medical Oncology (ESMO) and the European SocieTy for Radiotherapy & Oncology (ESTRO). The three societies nominated authors to write the guidelines as well as reviewers to comment on them. These guidelines were approved by the EHNS Executive Board, the ESMO Guidelines Committee and the ESTRO Executive Board in June 2020. Ann. Oncol. 2020;31:1462–1475. doi: 10.1016/j.annonc.2020.07.011.
- Cepeda V, et al. Biochemical mechanisms of cisplatin cytotoxicity. Anti-cancer agents medicinal Chem. 2007;7:3–18. doi: 10.2174/187152007779314044.
- Magrini SM, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J. Clin. Oncol. 2016;34:427–435. doi: 10.1200/JCO.2015.63.1671.
- Lee Y-G, et al. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13–01) BMC Cancer. 2020;20:813. doi: 10.1186/s12885-020-07297-z.
- Holleran WM, DeGregorio MW. Evolution of high-dose cisplatin. Investigational N. Drugs. 1988;6:135–142.
- Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2016;8:776–791. doi: 10.1002/wnan.1390.
- Boztepe T, Castro GR, León IE. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. Int J. Pharm. 2021;605:120788. doi: 10.1016/j.ijpharm.2021.120788.
- Farooq MA, et al. Recent progress in nanotechnology-based novel drug delivery systems in designing of cisplatin for cancer therapy: an overview. Artif. Cells Nanomed. Biotechnol. 2019;47:1674–1692. doi: 10.1080/21691401.2019.1604535.
- Goldberg M, et al. Development of a nanoparticle-embedded chitosan sponge for topical and local administration of chemotherapeutic agents. J. Nanotechnol. Eng. Med. 2014;5:0409051–4090511. doi: 10.1115/1.4030899.
- Miyano K, et al. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells. J. Controlled Release. 2017;261:275–286. doi: 10.1016/j.jconrel.2017.06.021.
- Davidi ES, et al. Cisplatin-conjugated gold nanoparticles as a theranostic agent for head and neck cancer. Head. Neck. 2018;40:70–78. doi: 10.1002/hed.24935.
- Cohen SM, et al. Efficacy and toxicity of peritumoral delivery of nanoconjugated cisplatin in an in vivo murine model of head and neck squamous cell carcinoma. JAMA Otolaryngol. Head. Neck Surg. 2013;139:382–387. doi: 10.1001/jamaoto.2013.214.
- Endo K, et al. Tumor-targeted chemotherapy with the nanopolymer-based drug NC-6004 for oral squamous cell carcinoma. Cancer Sci. 2013;104:369–374. doi: 10.1111/cas.12079.
- Kim JH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J. Controlled Release Off. J. Controlled Release. Soc. 2008;127:41–49. doi: 10.1016/j.jconrel.2007.12.014.
- Lin J, Alexander-Katz A. Cell membranes open “doors” for cationic nanoparticles/biomolecules: insights into uptake kinetics. ACS Nano. 2013;7:10799–10808. doi: 10.1021/nn4040553.
- Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenes Res. 2010;2:14. doi: 10.1186/2040-2384-2-14.
- Ferreira MBA, Lima JPSN, Cohen EEW. Novel targeted therapies in head and neck cancer. Expert Opin. Investigational Drugs. 2012;21:281–295. doi: 10.1517/13543784.2012.651455.
- Odukoya O, Schwartz J, Weichselbaum R, Shklar G. An epidermoid carcinoma cell line derived from hamster 7,12- dimethylbenz[a]anthracene-induced buccal pouch tumors2. JNCI: J. Natl Cancer Inst. 1983;71:1253–1264.
- Vidya Priyadarsini R, et al. Gene expression signature of DMBA-induced hamster buccal pouch carcinomas: modulation by chlorophyllin and ellagic acid. PLoS ONE. 2012;7:e34628. doi: 10.1371/journal.pone.0034628.
- Chen D, Yang K, Zhang G, Mei J, Xiang L. Screen and analysis of key disease genes for precancerous lesions of oral buccal mucosa induced by DMBA in golden hamsters. Oncol. Lett. 2011;2:265–271. doi: 10.3892/ol.2010.228.
- Chiang CP, Huang WT, Lee JW, Hsu YC. Effective treatment of 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch precancerous lesions by topical photosan-mediated photodynamic therapy. Head. Neck. 2012;34:505–512. doi: 10.1002/hed.21761.
- Hsu YC, Yang DF, Chiang CP, Lee JW, Tseng MK. Successful treatment of 7,12-dimethylbenz(a)anthracene-induced hamster buccal pouch precancerous lesions by topical 5-aminolevulinic acid-mediated photodynamic therapy. Photodiagnosis Photodyn. Ther. 2012;9:310–318. doi: 10.1016/j.pdpdt.2012.03.003.
- Wang YY, et al. MAL-PDT inhibits oral precancerous cells and lesions via autophagic cell death. Oral. Dis. 2019;25:758–771. doi: 10.1111/odi.13036.
- Shen L, Xu Q, Li P, Zhou G. Efficacy of krypton laser photodynamic therapy for oral mucosa dysplasia in 9,10-dimethyl-1,2-benzanthracene-treated hamsters. Oncol. Lett. 2013;6:1358–1362. doi: 10.3892/ol.2013.1554.
- Chen D, et al. Screening the pathogenic genes and pathways related to DMBA (7,12-dimethylbenz[a]anthracene)-induced transformation of hamster oral mucosa from precancerous lesions to squamous cell carcinoma. Oncol. Lett. 2011;2:637–642. doi: 10.3892/ol.2011.293.
- Hann S, et al. Platinum determination by inductively coupled plasma-sector field mass spectrometry (ICP-SFMS) in different matrices relevant to human biomonitoring. Anal. Bioanal. Chem. 2003;376:198–204. doi: 10.1007/s00216-003-1861-x.
- Morrison JG, et al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J. Pharm. Biomed. Anal. 2000;24:1–10. doi: 10.1016/S0731-7085(00)00377-0.
- Wang, J. et al. The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry. Pharmaceuticals14, 104 (2021).
- Martinčič A, et al. A novel method for speciation of Pt in human serum incubated with cisplatin, oxaliplatin and carboplatin by conjoint liquid chromatography on monolithic disks with UV and ICP-MS detection. Talanta. 2013;116:141–148. doi: 10.1016/j.talanta.2013.05.016.
- Kulkarni U, Mahalingam R, Pather SI, Li X, Jasti B. Porcine buccal mucosa as an in vitro model: relative contribution of epithelium and connective tissue as permeability barriers. J. Pharm. Sci. 2009;98:471–483. doi: 10.1002/jps.21436.
- Kinikoglu B, Hemar J, Hasirci V, Breton P, Damour O. Feasibility of a porcine oral mucosa equivalent: a preclinical study. Artif. Cells Blood Substit. Biotechnol. 2012;40:271–274. doi: 10.3109/10731199.2011.644293.
- Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J. Clin. 2002;52:195–215. doi: 10.3322/canjclin.52.4.195.
- Ribeiro AS, Salles PR, da Silva TA, Mesquita RA. A review of the nonsurgical treatment of oral leukoplakia. Int. J. Dent. 2010;2010:186018. doi: 10.1155/2010/186018.
- Chau L, et al. Topical agents for oral cancer chemoprevention: a systematic review of the literature. Oral. Oncol. 2017;67:153–159. doi: 10.1016/j.oraloncology.2017.02.014.
- Chow SC, Tu YH. On two-stage seamless adaptive design in clinical trials. J. Formos. Med Assoc. 2008;107:52–60. doi: 10.1016/S0929-6646(09)60009-7.
- Shan G, Wilding GE, Hutson AD, Gerstenberger S. Optimal adaptive two-stage designs for early phase II clinical trials. Stat. Med. 2016;35:1257–1266. doi: 10.1002/sim.6794.
- Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials. 1989;10:1–10. doi: 10.1016/0197-2456(89)90015-9.
- Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3:1351–1371. doi: 10.3390/cancers3011351.
- Gouyette A, Apchin A, Foka M, Richard JM. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur. J. Cancer Clin. Oncol. 1986;22:257–263. doi: 10.1016/0277-5379(86)90389-5.
- Rajkumar P, et al. Cisplatin concentrations in long and short duration infusion: implications for the optimal time of radiation Delivery. J. Clin. Diagnostic Res JCDR. 2016;10:XC01–XC04.
- Nguyen N, et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head. neck. 2016;38:1074–1084. doi: 10.1002/hed.24406.
- Fang J, et al. Prognostic significance of tumor infiltrating immune cells in oral squamous cell carcinoma. BMC cancer. 2017;17:375. doi: 10.1186/s12885-017-3317-2.
- Balermpas P, et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br. J. Cancer. 2014;110:501–509. doi: 10.1038/bjc.2013.640.
- de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2014;20:5384–5391. doi: 10.1158/1078-0432.CCR-14-1298.
- Wakita D, et al. Cisplatin augments antitumor T-cell responses leading to a potent therapeutic effect in combination with PD-L1 blockade. Anticancer Res. 2019;39:1749–1760. doi: 10.21873/anticanres.13281.
- Broner EC, et al. Doublecortin-like kinase 1 (DCLK1) is a novel NOTCH pathway signaling regulator in head and neck squamous cell carcinoma. Front Oncol. 2021;11:677051. doi: 10.3389/fonc.2021.677051.
- Sankar V, et al. Local drug delivery for oral mucosal diseases: challenges and opportunities. Oral. Dis. 2011;17:73–84. doi: 10.1111/j.1601-0825.2011.01793.x.
- Gupta V, Karthikeyan C, Trivedi P. Localized delivery of cisplatin for the effective management of squamous cell carcinoma from protransfersome formulation. Arch. Pharm. Res. 2012;35:851–859. doi: 10.1007/s12272-012-0510-3.
- Sudha T, et al. Targeted delivery of cisplatin to tumor xenografts via the nanoparticle component of nano-diamino-tetrac. Nanomed. 2017;12:195–205. doi: 10.2217/nnm-2016-0315.
- Wenig BL, et al. The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head. Neck Surg. 2002;128:880–885. doi: 10.1001/archotol.128.8.880.
- Li J, et al. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS ONE. 2012;7:e33860. doi: 10.1371/journal.pone.0033860.
- Desai KGH. Polymeric drug delivery systems for intraoral site-specific chemoprevention of oral cancer. J. Biomed. Mater. Res B Appl Biomater. 2018;106:1383–1413. doi: 10.1002/jbm.b.33943.
- Hu D, et al. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model. Arch. Otolaryngol.–Head. Neck Surg. 2012;138:412–417. doi: 10.1001/archoto.2012.20.
- Lan X, et al. Microneedle-mediated delivery of lipid-coated cisplatin nanoparticles for efficient and safe cancer therapy. ACS Appl. Mater. interfaces. 2018;10:33060–33069. doi: 10.1021/acsami.8b12926.
- Cai S, Xie Y, Davies NM, Cohen MS, Forrest ML. Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck. Therapeutic Deliv. 2010;1:237–245. doi: 10.4155/tde.10.38.
- Osada A, et al. 132 Poster - Phase IIa/IIb clinical trial of NC-6004 (Nanoparticle Cisplatin) plus Pembrolizumab in patients with head and neck cancer (HNSCC) who have failed platinum or a platinum-containing regimen. Eur. J. Cancer. 2020;138:S35. doi: 10.1016/S0959-8049(20)31164-3.
- Agrawal N, et al. A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC) J. Clin. Oncol. 2021;39:6056–6056. doi: 10.1200/JCO.2021.39.15_suppl.6056.
- Calixto G, Bernegossi J, Fonseca-Santos B, Chorilli M. Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int. J. Nanomed. 2014;9:3719–3735. doi: 10.2147/IJN.S61670.
- Zhang M, et al. Current trends of targeted drug delivery for oral cancer therapy. Front. Bioeng. Biotechnol. 2020;8:618931. doi: 10.3389/fbioe.2020.618931.
- Quiñones, J. P., Peniche, H. & Peniche, C. Chitosan based self-assembled nanoparticles in drug delivery. Polymers (Basel)10 (2018).
- Delan WK, et al. Formulation of simvastatin chitosan nanoparticles for controlled delivery in bone regeneration: optimization using Box-Behnken design, stability and in vivo study. Int. J. Pharmaceutics. 2020;577:119038. doi: 10.1016/j.ijpharm.2020.119038.
- Duceppe N, Tabrizian M. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery. Expert Opin. Drug Deliv. 2010;7:1191–1207. doi: 10.1517/17425247.2010.514604.
- Elgadir MA, et al. Impact of chitosan composites and chitosan nanoparticle composites on various drug delivery systems: a review. J. Food Drug Anal. 2015;23:619–629. doi: 10.1016/j.jfda.2014.10.008.
- Wang JJ, et al. Recent advances of chitosan nanoparticles as drug carriers. Int J. Nanomed. 2011;6:765–774.
- Remuñán-López C, Lorenzo-Lamosa ML, Vila-Jato JL, Alonso MJ. Development of new chitosan-cellulose multicore microparticles for controlled drug delivery. Eur. J. Pharm. Biopharm. 1998;45:49–56. doi: 10.1016/S0939-6411(97)00122-7.
- Mazzarino L, et al. Curcumin-loaded chitosan-coated nanoparticles as a new approach for the local treatment of oral cavity cancer. J. Nanosci. Nanotechnol. 2015;15:781–791. doi: 10.1166/jnn.2015.9189.
- Costa Idos S, Abranches RP, Garcia MT, Pierre MB. Chitosan-based mucoadhesive films containing 5-aminolevulinic acid for buccal cancer’s treatment. J. Photochem Photobio. B. 2014;140:266–275. doi: 10.1016/j.jphotobiol.2014.08.005.
- Remuñán-López C, Portero A, Vila-Jato JL, Alonso MJ. Design and evaluation of chitosan/ethylcellulose mucoadhesive bilayered devices for buccal drug delivery. J. Control Release. 1998;55:143–152. doi: 10.1016/S0168-3659(98)00044-3.
- Staffhorst RW, et al. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts. Anti-cancer drugs. 2008;19:721–727. doi: 10.1097/CAD.0b013e328304355f.
- Alsmadi MM, Obaidat RM, Alnaief M, Albiss BA, Hailat N. Development, in vitro characterization, and in vivo toxicity evaluation of chitosan-alginate nanoporous carriers loaded with cisplatin for lung cancer treatment. AAPS PharmSciTech. 2020;21:191. doi: 10.1208/s12249-020-01735-8.
- Fröhlich E. The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles. Int. J. Nanomed. 2012;7:5577–5591. doi: 10.2147/IJN.S36111.
- Werner JA, et al. A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel. Br. J. Cancer. 2002;87:938–944. doi: 10.1038/sj.bjc.6600588.
- Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model. J. Cell Biochem Suppl. 1993;17f:83–90. doi: 10.1002/jcb.240531012.
- Shklar G. Development of experimental oral carcinogenesis and its impact on current oral cancer research. J. Dent. Res. 1999;78:1768–1772. doi: 10.1177/00220345990780120101.
- Manimaran A, Manoharan S. Tumor preventive efficacy of emodin in 7,12-Dimethylbenz[a]Anthracene-induced oral carcinogenesis: a histopathological and biochemical approach. Pathol. Oncol. Res. POR. 2018;24:19–29. doi: 10.1007/s12253-017-0205-7.
- Chen YK, Hsue SS, Lin LM. Correlation between inducible nitric oxide synthase and p53 expression for DMBA-induced hamster buccal-pouch carcinomas. Oral. Dis. 2003;9:227–234. doi: 10.1034/j.1601-0825.2003.02878.x.
- Li Q, et al. Mouse tumor-bearing models as preclinical study platforms for oral squamous cell carcinoma. Front Oncol. 2020;10:212. doi: 10.3389/fonc.2020.00212.
- Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. BioMed. Res. Int. 2014;2014:967826. doi: 10.1155/2014/967826.
- Haya-Fernandez MC, Bagan JV, Murillo-Cortes J, Poveda-Roda R, Calabuig C. The prevalence of oral leukoplakia in 138 patients with oral squamous cell carcinoma. Oral. Dis. 2004;10:346–348. doi: 10.1111/j.1601-0825.2004.01031.x.
- Mehanna HM, Rattay T, Smith J, McConkey CC. Treatment and follow-up of oral dysplasia - a systematic review and meta-analysis. Head. Neck. 2009;31:1600–1609. doi: 10.1002/hed.21131.
- Silverman S, Jr., Gorsky M, Lozada F. Oral leukoplakia and malignant transformation. A follow-up study of 257 patients. Cancer. 1984;53:563–568. doi: 10.1002/1097-0142(19840201)53:3<563::AID-CNCR2820530332>;2-F.
- Lorini, L. et al. Overview of oral potentially malignant disorders: from risk factors to specific therapies. Cancers13, 3696 (2021).
- Eisen DB, et al. Guidelines of care for the management of actinic keratosis. J. Am. Acad. Dermatol. 2021;85:e209–e233. doi: 10.1016/j.jaad.2021.02.082.
- Yardimci G, Kutlubay Z, Engin B, Tuzun Y. Precancerous lesions of oral mucosa. World J. Clin. cases. 2014;2:866–872. doi: 10.12998/wjcc.v2.i12.866.
- Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ. The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation. Carcinogenesis. 1997;18:329–338. doi: 10.1093/carcin/18.2.329.
- Woolgar JA, Rogers SN, Lowe D, Brown JS, Vaughan ED. Cervical lymph node metastasis in oral cancer: the importance of even microscopic extracapsular spread. Oral. Oncol. 2003;39:130–137. doi: 10.1016/S1368-8375(02)00030-1.
- Tran L, et al. Cisplatin alters antitumor immunity and synergizes with PD-1/PD-L1 inhibition in head and neck squamous cell carcinoma. Cancer Immunol. Res. 2017;5:1141–1151. doi: 10.1158/2326-6066.CIR-17-0235.
- Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharm. 1989;24:148–154. doi: 10.1007/BF00300234.
- Jung SH, Lee T, Kim K, George SL. Admissible two-stage designs for phase II cancer clinical trials. Stat. Med. 2004;23:561–569. doi: 10.1002/sim.1600.
Source: PubMed